On July 16, Humana rose 4.85% in regular trading, trading at $414.745/share, with turnover of $68.13 million. The stock rallied alongside a broad healthcare sector rebound following the previous session's widespread selloff.

On the news front, several investment banks recently raised their price targets on Humana in rapid succession: Truist lifted its target from $320 to $415, Royal Bank of Canada raised its target significantly from $246 to $415, both maintaining Hold ratings, while Bernstein previously raised its target to $425 maintaining an Outperform rating. Sector peer UnitedHealth surged 8.66%, leading the managed care industry higher after the July 15 session saw broad declines with Centene down 8%, Molina down 4%, and Humana down 1.2%. The rebound was further supported by favorable tailwinds including improved 2027 Medicare Advantage final rate notices and Humana's recent selection for the Illinois Medicaid managed care contract expansion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)